Coversyl Plus - Treating hypertension and improving clinical outcomes in T2D and other high risk groups

Many patients with hypertension require combination therapy to reduce their blood pressure to target levels. Treatment with an angiotensin-converting enzyme (ACE) inhibitor such as perindopril, plus a diuretic such as indapamide, is frequently used to control hypertension. Coversyl Plus combines perindopril, 4 mg, and indapamide, 1.25 mg, in a single tablet, taken once daily, and thus can simplify treatment schedules and increase patient compliance. Coversyl Plus can reduce blood pressure to a greater extent than monotherapy with some other antihypertensive agents, and to an equivalent extent to certain other combination regimens. Results from a recent, large-scale clinical outcomes study have also shown that Coversyl Plus reduces the risk of premature death, micro- and macrovascular outcomes, and renal outcomes (such as the development of microalbuminuria) in hypertensive patients with type 2 diabetes. Importantly, these benefits appear to be independent of a range of treatments and the presence or absence of hypertension at baseline. Coversyl Plus is associated with an excellent safety and tolerability profile, and thus remains a valuable treatment option for hypertension. In addition, Coversyl Plus has been shown to be of particular benefit in significantly reducing risk in hypertensive patients with type 2 diabetes.